SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Endocrinology Referral — Ann Richards

PatientAnn Richards
Date of birth1962-09-01
IdentifiersMRN HR-ML019-SYN; SSN (made up) 000-19-3381
Document date2026-02-10
AuthorRosalind Teague, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Referral

Low bone mass on DXA with a FRAX risk above the treatment thresholds in a 63-year-old woman after a fall with a hand fracture. Please confirm how to classify her, whether to treat and with what, and how to monitor. [S]

Urgency: Routine, within four weeks. [S]

Questions for the consultant:

History of Present Illness

Postmenopausal since her early fifties, no hormone therapy, no glucocorticoids. Fell from standing height last year and broke her hand; one account also describes a second fall with an ankle fracture. She was told after an earlier test that she had early bone loss; no report is available. Her mother had osteoporosis with arm and hip fractures. Former heavy smoker, quit more than fifteen years ago; alcohol use disorder in sustained remission for more than fifteen years. Height 164.0 cm, about 2 cm below her recalled tallest; BMI 24.5. DXA today: lumbar spine T-score -2.3, femoral neck -2.0, total hip -1.7. Lateral spine DXA: no vertebral fracture. FRAX with femoral neck BMD (previous fracture and parental hip fracture entered): 22 percent major osteoporotic, 3.6 percent hip. Calcium 9.4, albumin 4.2, phosphate, magnesium, alkaline phosphatase, PTH 54, creatinine 0.8 (eGFR 81), TSH, and hemoglobin normal; 25-hydroxyvitamin D 24 ng/mL; fasting CTX 560 pg/mL; 24-hour urine calcium ordered. Calcium intake about 800 mg a day. Timed Up and Go 11 seconds, tandem stance 8 seconds. Started vitamin D3 2000 units daily today [S]

Historical basis. These claims are historical evidence, not findings from a modern examination.

4 later historical claims are omitted because they describe events after the index age. See the teaching note.

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Cholecalciferol (vitamin D3) 50 mcg (2000 units) oral tablet, one tablet dailyOne tablet by mouth dailyOral route2026-02-10activeS

Problems

ProblemClinical statusVerificationCodeProvenance
Low bone mass (osteopenia) of the lumbar spine and hip on DXA, lowest T-score -2.3 at the lumbar spine (femoral neck -2.0, total hip -1.7), with a 10-year FRAX risk above the treatment thresholds (major osteoporotic fracture 22 percent, hip 3.6 percent); not osteoporosis by T-score, but meets the AACE 2020 clinical criteria for osteoporosis (low bone mass with a FRAX risk above threshold)activeconfirmed M85.89S — Synthetic modern DXA and FRAX classification linked to her publicly described osteopenia (early osteoporosis) after a fall with a hand fracture.
Alcohol use disorder in sustained remission for more than fifteen years, since treatment; no alcohol sinceactiveconfirmed F10.21S — Synthetic modern coding of her publicly described heavy drinking and long recovery; listed because remission protects bone and lowers fall risk, and it is reviewed at each visit.
History of falls: a fall from standing height with a hand fracture last year (and, in one account, a second fall with an ankle fracture); no falls sinceactiveconfirmed Z91.81S — Synthetic modern entry linked to her publicly described falls and fractures.

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
1980Heavy drinking, followed by treatment from which she emerged sober; no alcohol sinceD (CLM-0003)
1996Fall with a hand fracture (one account also describes a second fall with an ankle fracture); the year is 1996 in two sources and 1994 in oneD (CLM-0006)
1996Bone density test after the fall, reported as osteopenia, an early stage of osteoporosis; no report or T-scores availableD (CLM-0005, CLM-0007)

Family History

RelativeConditionAge at deathEvidence
motherOsteoporosis with fractures of the arm and hip and a curved upper back, by Richards's own public account; Richards said osteoporosis was not the cause of her mother's death but led to itD (CLM-0004)

Social History

Vital Signs

DateMeasureValueUnitProvenance
2026-02-10Body height164cmS
2026-02-10Body weight66kgS
2026-02-10Body mass index (BMI) [Ratio]24.5kg/m2S
2026-02-10Systolic blood pressure124mm[Hg]S
2026-02-10Diastolic blood pressure76mm[Hg]S
2026-02-10Heart rate72/minS
2026-02-10Respiratory rate14/minS
2026-02-10Body temperature36.6CelS
2026-02-10Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-02-10DXA Lumbar spine [T-score] Bone density-2.3{T-score}-1.0 or higher is normal; between -1.0 and -2.5 is low bone mass (osteopenia); -2.5 or lower is osteoporosisLowS
2026-02-10DXA Femur [T-score] Bone density-2{T-score}-1.0 or higher is normal; between -1.0 and -2.5 is low bone mass (osteopenia); -2.5 or lower is osteoporosisLowS
2026-02-10DXA Hip [T-score] Bone density-1.7{T-score}-1.0 or higher is normal; between -1.0 and -2.5 is low bone mass (osteopenia); -2.5 or lower is osteoporosisLowS
2026-02-10Major osteoporotic fracture 10-year probability [Likelihood] Fracture Risk Assessment22%S
2026-02-10Hip fracture 10-year probability [Likelihood] Fracture Risk Assessment3.6%S
2026-02-10Calcium [Mass/volume] in Serum or Plasma9.4mg/dL8.6-10.3 mg/dLNormalS
2026-02-10Albumin [Mass/volume] in Serum or Plasma4.2g/dL3.5-5 g/dLNormalS
2026-02-10Creatinine [Mass/volume] in Serum or Plasma0.8mg/dL0.5-1 mg/dLNormalS
2026-02-10Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M81mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-02-10Phosphate [Mass/volume] in Serum or Plasma3.5mg/dL2.5-4.5 mg/dLNormalS
2026-02-10Magnesium [Mass/volume] in Serum or Plasma2mg/dL1.7-2.4 mg/dLNormalS
2026-02-10Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma84U/L40-120 U/LNormalS
2026-02-10Parathyrin.intact [Mass/volume] in Serum or Plasma54pg/mL15-65 pg/mLNormalS
2026-02-10Thyrotropin [Units/volume] in Serum or Plasma1.9m[IU]/L0.4-4 mIU/LNormalS
2026-02-10Hemoglobin [Mass/volume] in Blood13.3g/dL12-15.5 g/dLNormalS
2026-02-10Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma21U/L7-35 U/LNormalS
2026-02-1025-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma24ng/mLTarget 30 ng/mL or higher before and during osteoporosis treatmentLowS
2026-02-10Collagen crosslinked C-telopeptide [Mass/volume] in Serum or Plasma560pg/mLPostmenopausal reference interval 104 to 1008 pg/mL; a fall of more than about 30 percent on antiresorptive therapy indicates responseNormalS
2026-02-10Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]2{score}S
2026-02-10Total score [AUDIT-C]0{score}S

Assessment

Plan of Treatment